CD19-targeted therapies, including CAR-T therapies and TCEs have demonstrated promising therapeutic potential in the treatment of autoimmune diseases. However, the clinical development of TCEs has ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer ...

ATG-107 (FLT3 x CD3 T-cell Engager) Title: ATG-107, a novel "2+1" CD3-based T-cell Engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML Abstract Number: 1068 ...

T-cell engager (TCE) treatment is a significant advancement in biomedicine, with transformative promise for treating autoimmune disorders and cancer. TCEs function as "immune navigation systems" in ...

Introduction: A "2+1" TCE Specifically Designed for Autoimmune Diseases Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial ...

Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in ...

We spotlight trailblazers in the entrepreneurship world, exploring their groundbreaking ventures, innovative strategies, and the latest trends shaping the business landscape. Your daily digest of the ...